跳至主要内容
临床试验/NCT07323043
NCT07323043招募中不适用

The Affiliated Lianyungang Hospital of Xuzhou Medical University

The First People's Hospital of Lianyungang1 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2026年1月15日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
190
试验地点
1
主要终点
Incidence of choking cough response

研究概览

简要总结

In patients undergoing general anesthesia with planned tracheal intubation , a prospective, randomized, controlled study was conducted to record the occurrence of cough 2 minutes after injection of Sufentanil or Tegilerdine. The cough was graded based on the frequency and duration: Grade I, no cough; Grade II, a single mild cough; Grade III, multiple coughs with duration <1 second; Grade IV, continuous coughing with a duration >15 seconds.

详细描述

Using a computer-generated randomized number table, patients were divided into two groups: the experimental group receiving Tiliglitidine (T group) at 20-50ug/kg, and the control group receiving Sufentanil (S group) at 0.2-0.4 μg/kg. After patients arrived in the operating room, routine monitoring including non-invasive blood pressure, electrocardiogram, and oxygen saturation was performed, and intravenous access was established. Patients were oxygenated and given the study drug before anesthesia induction. No other drugs were administered to the patients before giving the study drug. During anesthesia induction, patients received intravenous injection of Tiliglitide or Sufentanil according to their group. The severity of coughing was graded based on the number of coughing episodes: graded by the number and duration of coughs: Grade I, no cough, breathing regular; Grade II, a single mild cough; Grade III, multiple coughs, lasting less than 15 seconds; Grade IV, continuous coughs, lasting more than 15 seconds.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 and 65 years, 18 ≤ BMI (kg/m²) ≤ 30;
  • ASA grade I ~ III;
  • Scheduled elective surgery under general anesthesia with tracheal intubation.

排除标准

  • Patients with chronic cough (cough lasting >8 weeks) or asthma;
  • Patients with a history of allergy to the drugs used during the study;
  • Patients with severe cardiovascular disease, intracranial lesions, eye lesions, or lung lesions.

研究组 & 干预措施

Sufentanil group

Active Comparator

Administer sufentanil 0.2-0.4 µg/kg before the induction of general anesthesia, and record the patient's coughing episodes 2 minutes after administration. Then proceed with anesthesia induction.

干预措施: Sufentanil (Drug)

Tegilerdine group

Experimental

Administer 20-50µ/kg of Tegilerdine before induction of general anesthesia, and record the patient's coughing episodes 2 minutes after administration. Then proceed with anesthesia induction.

干预措施: Tegilerdine (Drug)

结局指标

主要结局

Incidence of choking cough response

时间窗: 2 minutes after administration

Two minutes after administration of the study drugs (Tegilerdine/Sufentanil), any clear coughing action is considered an 'occurrence'.

次要结局

  • Blood pressure(before injection of Tegilerdine or Sufentanil (T0), 2 minutes after injection (T1), 1 minute before intubation (T2), 1 minute after intubation (T3), and 3 minutes after intubation (T4))
  • Heart rate(before injection of Tegilerdine or Sufentanil (T0), 2 minutes after injection (T1), 1 minute before intubation (T2), 1 minute after intubation (T3), and 3 minutes after intubation (T4))
  • Grading of choking and coughing response(2 minutes after administration)
  • Blood pressure(before injection of Tegilidine or Sufentanil (T0), 2 minutes after injection (T1), 1 minute before intubation (T2), 1 minute after intubation (T3), and 3 minutes after intubation (T4))
  • Heart rate(before injection of Tegilidine or Sufentanil (T0), 2 minutes after injection (T1), 1 minute before intubation (T2), 1 minute after intubation (T3), and 3 minutes after intubation (T4))
  • Adverse reaction(2 minutes after administration)

研究者

发起方
The First People's Hospital of Lianyungang
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验